SCHEMBL13471998

SCHEMBL13471998

COc1cc2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2cc1OCCCN1CCN(C)CC1

nearest known ligand 0.89

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 11/20 0.89
RET P07949 5/20 0.89
FLT4 P35916 4/20 0.89
PDGFRB P09619 4/20 0.89
TEK Q02763 3/20 0.89
AURKB Q96GD4 3/20 0.89
EGFR P00533 2/20 0.89
FGFR1 P11362 2/20 0.89
FLT1 P17948 2/20 0.89
PLK4 O00444 1/20 0.89
GAK O14976 1/20 0.89
EPHB6 O15197 1/20 0.89
RIPK2 O43353 1/20 0.89
ERN1 O75460 1/20 0.89
STK10 O94804 1/20 0.89
MAP4K4 O95819 1/20 0.89
CHEK2 O96017 1/20 0.89
ABL1 P00519 1/20 0.89
ERBB2 P04626 1/20 0.89
LCK P06239 1/20 0.89

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3198096 1.00 KDR (0.89) KDRRETFLT4PDGFRBTEK
SCHEMBL1401668 0.95 KDR (0.89) KDRRETFLT4PDGFRBTEK
Cediranib SCHEMBL29368143 0.94 KDR (1.00) KDRRETFLT4PDGFRBTEK
Cediranib SCHEMBL63147 0.94 KDR (1.00) KDRRETFLT4PDGFRBTEK
Cediranib SCHEMBL29383181 0.94 KDR (1.00) KDRRETFLT4PDGFRBTEK
Cediranib SCHEMBL29351458 0.94 KDR (1.00) KDRRETFLT4PDGFRBTEK
SCHEMBL1685423 0.93 ABCB11 (1.00) KDRRETFLT4PDGFRBTEK
SCHEMBL1401641 0.93 KDR (0.88) KDRRETFLT4PDGFRBTEK
SCHEMBL14421787 0.93 KDR (0.88) KDRRETFLT4PDGFRBTEK
SCHEMBL1401636 0.92 KDR (0.84) KDRRETFLT4PDGFRBTEK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293902-B2 Quinazoline compounds ASTRAZENECA AB (SE) 2012-10-23 US disclosed
US-20090156821-A1 Quinazoline compounds ASTRAZENECA AB 2009-06-18 US disclosed
US-20080027069-A1 Quinazoline compounds ASTRAZENECA AB 2008-01-31 US disclosed
US-7268230-B2 Quinazoline compounds ASTRAZENECA AB (SE) 2007-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156821-A1 Quinazoline compounds VEGFA, FLT4, FLT1 KDR 5/4885RET 2725/4885FLT4 2/4885
US-20080027069-A1 Quinazoline compounds VEGFA, FLT4, FLT1 KDR 5/4885RET 2725/4885FLT4 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.